TRON @ Twitter:

Knocking out the TGFb II receptor improves #CARTcell capabilities in #tumor killing and resistance to anti-proliferative effects. #immunotherapy

Exciting news! #DFG will fund CRC1292 for 4 more years to target inefficient #immunity in #tumors and #chronic #infections, to which TRON contributes two projects.
We look forward to continuing the collaboration with our excellent partners. About CRC1292:

Wir vergrößern unser Team im #Projektmanagement! Dazu suchen wir eine:n Senior Projektmanager:in (m/w/d) mit langjähriger Erfahrung in interdisziplinären und/oder internationalen Teams zur Koordination unserer Forschungs- und Kooperationsprojekte.

We are expanding our #PhDprogram and are looking for a Scientific Training Program #Coordinator (m/f/d). The tasks include the coordination and expansion of our existing program, and the development of an internationally competitive training network.

Innovation durch Vernetzung: Unser Clusterkonzept #curATime zusammen mit @UnimedizinM und @DFKI ist in die Konzeptionsphase der BMBF #Zukunftscluster Initiative gestartet. Eine Beteiligung weiterer Firmen und Einrichtungen ist möglich. mehr dazu hier:
tronmainz photo

We are expanding our Personalized Cancer Genomics Team and are hiring a #Bioinformatics/Data #Scientist (m/f/d) to support the development of our personalized #cancer vaccines platform and the integration into existing clinical processes.





Press Releases

  • Official foundation ceremony of HI-TRON Mainz (Feburary, 2019)
  • Cooperation agreements signed between TRON and DKFZ to found HI-TRON Mainz (August, 2018)
  • Prof. Ugur Sahin receives prestigious European Research Council (ERC) Advanced Grant for personalized cancer vaccines (April, 2018)
  • TRON receives three-year research grant from the Falconwood Foundation to develop new treatment approaches for neuroendocrine tumors (February, 2018)
  • TRON collaborates with its industrial partner BioNTech in a first-ever clinical study demonstrating that personalized RNA-based vaccines using mutant neo-epitopes as antigens activate immune system against individual mutations and exert anti-cancer activity. (July, 2017)
  • TRON as a partner in a collaboration with industrial and academic experts in the field of immunology and cancer research, to develop, improve and optimize immunomodulatory concepts for increased efficacy and improved tolerability of cancer immunotherapies. (June, 2015)  
  • TRON is a partner in the newly established multi-partnered Horizon 2020 funded consortium APERIM, which will collaborate on the practical implementation of immunotherapy and the development of a new treatment platform specifically for unique tumour mutations of individual patients. (May 1, 2015) 
  • Auf dem Weg zu einer individualisierten Immuntherapie bei Krebs
    Neue immunologische Erkenntnisse und technologische Fortschritte ebnen den Weg für maßgeschneiderte Krebsimpfstoffe / klinische Studie läuft bereits (March 23, 2015). 
  • TRON and TheraCode together with Merck begin collaboration on identification and development of biomarkers for antigen-specific cancer immunotherapy (October 18, 2012).
  • First preclinical proof-of-concept of mutation-based individualized cancer vaccine. Deep sequencing of immunogenic mutations may pave way for customized immunotherapy (Jan 17, 2012). 
  • New Variant Analysis Software from Ingenuity Used to Identify DNA Variants for Personalized Medicine Research (Jan 9, 2012). 
  • Der Brückenschlag: Translationale Medizin.
    (© Das PDF zum Wissenschaftsmagazin dient lediglich der privaten Verwendung, es darf nicht kommerziell vervielfältigt und verbreitet werden. Alle Rechte liegen bei der Tempus Corporate GmbH)
  • New Convey Graph Constructor Leverages Hybrid-Core Architecture to Speed De Novo Genome Assembly (May 17, 2011). 
  • Next-generation sequencing technology for medicine and research in Mainz. Center for Translational Oncology and Immunology (TRON) Mainz has received one of the world’s first Illumina HiSeq genome sequencers (June 6, 2010).